CD22 and acute lymphoblastic leukemia: On 6 March 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer, New York, NY, USA) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor ALL [6].